1.1 Failure to induce global/clinical remission |
11 |
2387 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.82, 0.89] |
1.1.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.84, 1.02] |
1.1.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
8 |
956 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.82, 0.94] |
1.1.3 Dose of 5‐ASA: ≥ 3 g |
8 |
1200 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.83 [0.77, 0.88] |
1.2 Failure to induce global/clinical improvement (including remission) |
14 |
2256 |
Risk Ratio (M‐H, Random, 95% CI) |
0.68 [0.61, 0.75] |
1.2.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Random, 95% CI) |
0.79 [0.64, 0.97] |
1.2.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
10 |
877 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.67, 0.88] |
1.2.3 Dose of 5‐ASA: ≥ 3 g |
9 |
1148 |
Risk Ratio (M‐H, Random, 95% CI) |
0.57 [0.51, 0.65] |
1.3 Failure to induce endoscopic remission |
4 |
1154 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.67, 0.89] |
1.3.1 Dose of 5‐ASA: < 2 g |
1 |
122 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.64, 1.14] |
1.3.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
3 |
393 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.70, 1.05] |
1.3.3 Dose of 5‐ASA: ≥ 3 g |
4 |
639 |
Risk Ratio (M‐H, Random, 95% CI) |
0.70 [0.56, 0.87] |
1.4 Failure to induce endoscopic improvement (including remission) |
4 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.59, 0.86] |
1.4.1 Dose of 5‐ASA: 2 ‐ 2.9 g |
3 |
265 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.73 [0.58, 0.92] |
1.4.2 Dose of 5‐ASA: ≥ 3 g |
2 |
151 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.69 [0.49, 0.96] |
1.5 Adverse events |
8 |
1218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.85, 1.07] |
1.5.1 Dose of 5‐ASA: < 2 g |
1 |
30 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [0.74, 2.13] |
1.5.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
5 |
377 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.82, 1.33] |
1.5.3 Dose of 5‐ASA: ≥ 3 g |
5 |
811 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.80, 1.05] |
1.6 Serious adverse events |
4 |
746 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.53 [0.18, 1.56] |
1.6.1 Dose of 5‐ASA: 2 ‐ 2.9 g |
3 |
243 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.14, 3.33] |
1.6.2 Dose of 5‐ASA: ≥ 3 g |
3 |
503 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.44 [0.10, 1.92] |
1.7 Withdrawals due to adverse events |
13 |
2372 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.54, 0.97] |
1.7.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.19, 1.63] |
1.7.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
9 |
926 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.65, 1.94] |
1.7.3 Dose of 5‐ASA: ≥ 3 g |
9 |
1215 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.59 [0.41, 0.87] |
1.8 Exclusions and withdrawals after study entry |
15 |
2529 |
Risk Ratio (M‐H, Random, 95% CI) |
0.61 [0.51, 0.72] |
1.8.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Random, 95% CI) |
0.64 [0.42, 0.98] |
1.8.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
11 |
1014 |
Risk Ratio (M‐H, Random, 95% CI) |
0.70 [0.53, 0.92] |
1.8.3 Dose of 5‐ASA: ≥ 3 g |
10 |
1284 |
Risk Ratio (M‐H, Random, 95% CI) |
0.52 [0.41, 0.66] |